The U.S. Food and Drug Administration approved Cobenfy on September 26, 2024, making it the first schizophrenia drug with a ...
LOS ANGELES — The novel phosphodiesterase 10A (PDE10A) inhibitor known as CPL'36 (Celon Pharma) is effective and generally safe in acute exacerbations of schizophrenia, new research suggested. In a ...
Significant side effects of this medication include extrapyramidal symptoms, or involuntary movements and muscle stiffness, which can lead to motor deficits like those seen in patients with ...